Omega 3 Prescription Drugs Market Report 2026

The omega 3 prescription drugs market size has grown strongly in recent years. It will grow from $1.75 billion in 2025 to $1.92 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to high prevalence of hypertriglyceridemia, rising awareness of cardiovascular diseases, increasing geriatric population, availability of prescription omega-3 drugs, growth in clinical research and trials.

The omega 3 prescription drugs market size is expected to see strong growth in the next few years. It will grow to $2.81 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to advancements in precision medicine, rising demand for personalized therapies, integration of digital health tools, expansion in emerging markets, innovation in omega-3 drug formulations. Major trends in the forecast period include personalized omega-3 therapy development, increased clinical trials for omega-3 formulations, growth in cardiovascular risk management solutions, expansion of prescription omega-3 drug accessibility, enhanced nutraceutical-pharmaceutical integration.

Rising cases of cardiovascular diseases (CVDs) are expected to drive growth in the omega-3 prescription drug market. Elevated blood triglyceride levels, a fatty-like substance, are associated with an increased risk of cardiovascular disorders, and omega-3 supplements help regulate and reduce these triglyceride levels. For example, in August 2025, according to the National Institutes of Health, a US-based government agency, between 2025 and 2050, cardiovascular prevalence is projected to rise by 90%, mortality by 73%, and disability-adjusted life years (DALYs) by 55%, with deaths increasing from 20.5 million to 35.6 million. Consequently, the growing burden of cardiovascular diseases is expected to propel demand for omega-3 prescription drugs.

Leading companies in the omega-3 prescription drug market are focusing on product launches, such as capsules, which help lower the body’s production of triglycerides. Capsules are pharmaceutical or dietary supplement dosage forms, typically consisting of a gelatin or similar shell enclosing a specific amount of active ingredients in a convenient, ingestible format. For instance, in March 2023, Hikma Pharmaceuticals, a UK-based multinational company specializing in generic and in-licensed pharmaceutical products, launched Icosapent Ethyl Capsules, 0.5g, in the US. These capsules, containing eicosapentaenoic acid (EPA), are indicated for reducing triglyceride levels in adults with severe hypertriglyceridemia. This launch addresses the rising demand for pharmaceutical-grade omega-3 products and provides an effective therapy for high triglyceride levels.

In July 2024, KD Pharma, a Europe-based contract development and manufacturing organization (CDMO) specializing in pharmaceutical and nutritional lipids, acquired DSM-Firmenich’s MEG-3 fish oil business, including production facilities in Peru and Canada and around 200 employees, for an undisclosed amount. This strategic acquisition allows KD Pharma to strengthen its presence across the food, beverage, dietary supplement, and pharmaceutical sectors. DSM-Firmenich’s MEG-3 business is closely connected to omega-3 products.

Major companies operating in the omega 3 prescription drugs market are Pfizer Inc., Sanofi S.A., Amarin Corporation plc, GlaxoSmithKline plc, AstraZeneca plc, Merck & Co. Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, BASF SE, DSM Nutritional Products, AbbVie Inc., Eli Lilly and Company, Bayer AG, Shire Pharmaceuticals, Mylan NV, Teva Pharmaceutical Industries Ltd., Horizon Therapeutics, Kyowa Kirin Co. Ltd., Sumitomo Pharma Co. Ltd.

North America was the largest region in the omega 3 prescription drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omega 3 prescription drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the omega 3 prescription drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the omega-3 prescription drugs market by increasing the cost of imported raw materials and active pharmaceutical ingredients (APIs), which has elevated production costs and affected the availability of certain drug formulations. The segments most affected include combination EPA and DHA products like Lovaza and emerging formulations in clinical trials, particularly in regions such as North America and Europe that rely on imports. While the tariffs create cost pressures, they have also encouraged local manufacturing and supply chain diversification, which may strengthen domestic production capabilities and support long-term market resilience.

The omega 3 prescription drugs market research report is one of a series of new reports that provides omega 3 prescription drugs market statistics, including omega 3 prescription drugs industry global market size, regional shares, competitors with a omega 3 prescription drugs market share, detailed omega 3 prescription drugs market segments, market trends and opportunities, and any further data you may need to thrive in the omega 3 prescription drugs industry. This omega 3 prescription drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Omega-3 prescription drugs reduce triglyceride levels (a fat-like substance) in the blood and increase good cholesterol (HDL) levels. Omega-3 fatty acids are nutrients obtained from food or supplements that support overall health and are essential for building and maintaining every cell wall in the body.

The main types of omega-3 prescription drugs include Vascepa, Lovaza, and others. Vascepa is used in adults to lower the risk of heart attack, stroke, and certain heart conditions that require hospitalization. It is an FDA-approved medication for adults with high triglyceride levels and two or more additional cardiovascular risk factors, such as high blood pressure, high cholesterol, or obesity. Omega-3 prescription drugs are used to treat hypertriglyceridemia and other conditions, and they are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The omega 3 prescription drugs market consists of sales of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.